Do skip-N2 metastases significantly impact overall survival and disease-free interval in N2 NSCLC patients? A multicenter analysis.
暂无分享，去创建一个
F. Klauschen | M. Heldwein | T. Wahlers | C. Gaisendrees | N. Frost | K. Höpker | D. Horst | A. Quaas | G. Schlachtenberger | F. Doerr | H. Menghesha | R. Büttner | Jens-C Rueckert | S. Schallenberg | Khosro Hekmat | Corinna Grathwohl | J. Neudecker | A. Amorin | Hruy Menghesha